Argentina maintains one of the world’s most streamlined and predictable regulatory environments for gene-edited products. Under the current Resolution 24/2026, the country employs a product-based “prior consultation” system that distinguishes between New Breeding Techniques (NBTs) and traditional Genetically Modified Organisms (GMOs). The core legal standard is whether the final organism contains a “new combination of genetic material.” If the genetic change could have occurred naturally or through conventional breeding, the product is regulated as a conventional variety rather than a GMO, exempting it from the more rigorous biotechnology approvals. As with GMOs, Argentina has no specific GMO product-labeling regulations, although many manufacturers of products with GMOs voluntarily attached “Biotech Free” or “Non-GMO” labels. This product-based evaluation process mirrors what exists in the U.S. and Canada and is much more flexible than the EU process-based system.
This streamlined regulations are the culmination of more than a decade of legislative evolution. Argentina was an agricultural biotechnology pioneer in this space, beginning with Resolution 173/2015, which established the foundational framework for assessing New Breeding Techniques. It was refined in 2021 before being updated to the current standard, which provides a more robust “Instancia de Consulta Previa,” or Prior Consultation Instance, the primary gateway for developers seeking regulatory approval.
The National Advisory Commission on Agricultural Biotechnology (CONABIA) is the technical heart of this system. Developers engage with CONABIA through a consultation process where they submit a detailed dossier describing the organism, the techniques used, and the specific molecular changes. It uniquely allows for consultations on “hypothetical” products still in the design phase, providing scientists and companies with a regulatory forecast before they commit to expensive laboratory or field testing. The commission operates under a strict timeline, generally providing a response within 80 working days.
A product is handled under the full biotechnology approval track only if it meets specific criteria: the creation of a stable genetic insertion, a genotype that is impossible to obtain through conventional methods, and the generation of a novel expression product, such as a new protein, within the species’ gene pool. If these conditions are absent, the organism or animal is classified as non-GMO and regulated as a conventional product. This means it bypasses the intensive biosafety requirements for transgenic crops and is instead reviewed under the same quality and safety standards as any variety developed through traditional breeding.
The regulatory process for animals, microorganisms, and plants has been simplified under Resolution 24/2026, which replaced generic applications with specialized technical questionnaires tailored to each specific type of organism. These new forms act as a clear roadmap for scientists, allowing a cattle researcher or a microbiologist to provide exactly the data needed for their field without wading through irrelevant crop-based requirements. This 2026 update also refined the process by guaranteeing a government response within 80 working days and strengthening confidentiality rules to ensure that a developer’s proprietary research remains protected.
This approval framework has established Argentina as a global leader in animal gene editing regulations, with 22 animal cases since 2015, including cattle, horses, swine, and tilapia, having been evaluated as of May 2026. A landmark example is the FLT 01 tilapia; as early as 2019, regulators determined the line would not be classified as a GMO because it contained no foreign DNA, making Argentina one of the first countries to apply a product-based standard to a food animal. However, despite these successful regulatory determinations, gene-edited animals have not yet been commercialized in Argentina, as the sector remains focused on research and development.
NGO Reaction
Argentina’s non-governmental organizations (NGOs) have shifted from attacking what they claim is the biological “unnaturalness” of transgenics to a broader critique of the country’s agricultural model, which heavily relies on biotechnology. During the early 2000s, Greenpeace Argentina and Argentina sin Transgénicos branded GMOs “Frankenfoods,” arguing that foreign DNA across species boundaries posed fundamental risks. On the defensive with the advent of gene editing, and trapped by their former characterizations, they have attempted to frame cisgenics as “New Transgenics”, a term they use to argue that these products represent a continuation of the same industrial and corporate risks, regardless of the underlying science.
GRAIN, Naturaleza de Derechos and the Fundación Ambiente y Recursos Naturales (FARN) argue that classifying gene-edited products as non-GMO is “deregulation by definition,” creating a technical loophole that sidesteps constitutional requirements for public participation. Naturaleza de Derechos specifically challenges the institutional role of CONABIA, alleging that its closed-door evaluations lack transparency. Biodiversidad en América Latina and Greenpeace focus on the “technological package,” claiming that gene editing reinforces a destructive cycle of monoculture and chemical dependency that degrades rural land and water.
Asociación Argentina de Abogados/as Ambientalistas (AAdeAA) and the Animal Rights & Welfare network target the 2026 animal guidelines, arguing that productivity edits, such as high-muscle growth in FLT 01 tilapia, prioritize profit over animal welfare. They also raise alarms about what they call “ecosystem escape” risks, saying that because these hyper-productive animals are not classified as GMOs, they lack the stringent containment monitoring necessary to prevent native biodiversity from being devastated by escapees in Argentina’s river systems. The Argentine Polo Horse Association, concerned with the integrity of breeding and sport, maintains the “product-based” approach is expanding biotechnology without public consent.
Proponent Martin Lema defends the framework as “simple but solid” that correctly focuses on when a gene-edited crop should be evaluated as a conventional new variety rather than obsessing about the breeding method, the product rather than the process.
Updated: 05/11/2026
